Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors during the central nervous program, conolidine modulates alternate molecular targets. A Science Innovations examine uncovered that conolidine interacts While using the atypical chemokine receptor ACKR3/C